Global Anemia And Other Blood Disorder Drugs Market Growth Rate 2024, Forecast To 2033
8 Jan, 2024
The market for anemia and other blood disorder drugs has exhibited robust growth, surging from $11.13 billion in 2023 to $11.91 billion in 2024, showcasing a 7.0% compound annual growth rate (CAGR). Disease prevalence, global health initiatives, an aging population, and pharmaceutical innovation fueled historic period growth. Forecasts predict continued strength, reaching $15.49 billion in 2028 with a 6.8% CAGR. Emerging markets, global demographics, and economic factors, coupled with trends like research and development, technological advances, and biologics, contribute to the positive outlook.
Global Anemia And Other Blood Disorder Drugs Market Key Driver
The prevalence of anemia globally acts as a key driver for the anemia and other blood disorder drugs market. Unhealthy lifestyles, changing dietary habits, and increased stress levels contribute to a rise in anemia cases. Among the elderly (>65 years), anemia is the most frequent disease, reaching a prevalence rate of around 17%. The World Bank reports that anemia is the 8th leading cause of disease among women and the young population, driving the demand for drugs addressing anemia and other blood disorders.
Get A Free Sample Of The Global Anemia And Other Blood Disorder Drugs Market ReportGlobal Anemia And Other Blood Disorder Drugs Market Segments
The anemia and other blood disorder drugs market covered in this report is segmented –
1) By Type: Iron Deficiency Anemia, Chronic Kidney Disease Anemia, Sickle Cell Anemia, Aplastic Anemia
2) By Route of Administration: Oral, Injectable
3) By Distribution Channel: Hospitals Pharmacy, Online Pharmacy, Pharmacy
By Geography: The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions
North America was the largest region in the anemia and other blood disorder drugs market in 2023. Middle East is expected to be the fastest-growing region in the anemia and other blood disorder drugs market during the forecast period. The regions covered in the anemia and other blood disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Anemia And Other Blood Disorder Drugs Industry Players
Amgen Inc, GlaxoSmithKline plc, Akebia Therapeutics Inc., Bayer AG, Pfizer Inc, F. Hoffmann-La Roche Ltd., Merck Sharp & Dohme Corp., Novartis AG, Global Blood Therapeutics Inc., GlycoMimetics Inc., Eli Lilly and Company, FibroGen Inc., bluebird bio Inc., Acceleron Pharma Inc., AMAG Pharmaceuticals Inc., Pieris Pharmaceuticals Inc., Vifor Pharma Management Ltd., Sanofi S.A., Allergan U.S. Inc., Meda Consumer Healthcare Inc., AbbVie Inc., Johnson & Johnson, Daiichi Sankyo Company Limited, Galenica Ltd., Pharmacosmos A/S, Emmaus Medical Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb Company, Merck & Co. Inc., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., uniQure N.V., Rubius Therapeutics Inc., BioMarin Pharmaceutical Inc., Grifols S.A., Orchard Therapeutics plc
Get The Full Global Anemia And Other Blood Disorder Drugs Market Report
Anemia And Other Blood Disorder Drugs Market Overview
Anemia and Other Blood Disorder Drugs refer to the medications or drugs that are used to treat anemia and other blood disorder diseases. It refers to a blood condition that develops when a medication prompts the body's immune system to begin attacking its own red blood cells. Hemolysis, a process that causes red blood cells to degrade earlier than usual, is brought on by this.
Anemia And Other Blood Disorder Drugs Global Market Report 2023 provides data on the global anemia and other blood disorder drugs market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The anemia and other blood disorder drugs market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.